Muromonab-CD3 (brand name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant medication given to reduce acute rejection in people with organ transplants. [1] [2] It is a monoclonal antibody targeted at the CD3 receptor, [3] a membrane protein on the surface of T cells.

OKT3 has been found to be effective for induction of immunosuppression and for treating initial and steroid-resistant rejections. OKT3 is a murine monoclonal antibody of the immunoglobulin IgG2a isotype.

Muromonab-CD3 (also known as OKT3) is a murine IgG2a antibody directed at the ɛ-chain of CD3 that was first used in the setting of renal transplant induction therapy in the 1980s: it was shown to be effective in the treatment of acute allograft rejection.

2024年3月25日 · Orthoclone OKT3 package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

The OKT3 monoclonal antibody has unique reactivity for human T cells and induces a mitogenic response equal to that of concanavalin A (Con A). However, significant differences were found in activation requirements for the two T cell mitogens.

Muromonab CD3 (Orthoclone OKT3, Orthoclone, OKT3) is the first monoclonal antibody to become available for therapy in humans. In effect it blocks all cytotoxic T cell function. Clinical trials show that muromonab CD3 is effective in reversing acute renal, hepatic, cardiac and combined kidney-pancrea …

2024年5月16日 · Muronomab-CD3, also known by its trade name Orthoclone OKT3, is historically significant as it was the first monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for use in humans in 1986, for the prevention of kidney transplant rejection.

The anti-CD3 monoclonal antibody (OKT3) recognizes CD3, a human glycoprotein and member of the Ig superfamily—primarily expressed on T cells, some NKT cells, and thymocytes during T-cell differentiation. Binding of an anti-CD3 monoclonal antibody to CD3 stimulates T …

Experience with a second or third treatment with OKT3 indicates that OKT3 is ineffective clinically if the CD3 target molecule is not modulated. OKT3 has been found to be effective for induction of immunosuppression and for treating initial and steroid-resistant rejections.

1993年8月1日 · OKT3 is a monoclonal antilymphocyte antibody produced by a murine hybridoma technique. It differs from polyclonal antilymphocyte antibody preparations in that it is specific for one epitope of the T lymphocyte and is a pure product with batch-to-batch standardization.